Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Scopolamine placebo Clear all
Terminated Phase 2 Interventional Results available

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

NCT01312844
View directory record Official record
Conditions
Depression
Interventions
Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113
View directory record Official record
Conditions
Asthma
Interventions
tiotropium-bromide, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00871182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

NCT00737100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

NCT00950807
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo, GSK573179
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Tiotropium In Exercise

NCT00525512
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Exercise
Interventions
tiotropium 18 mcg, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT02796677
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
85
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One Year Study in COPD.

NCT00387088
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat, Tiotropium
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
3,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

NCT05161156
View directory record Official record
Conditions
COPD
Interventions
Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
Combination Product
Lead sponsor
Phargentis SA
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

NCT03386448
View directory record Official record
Conditions
Depression
Interventions
Scopolamine and naltrexone, placebo arm
Drug
Lead sponsor
The Taub Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 26, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD

NCT00239460
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sylmar, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

NCT00932737
View directory record Official record
Conditions
Abdominal Pain
Interventions
Placebo, HBB 20 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Westlake Village, California • Hollywood, Florida • Jupiter, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Dose Finding Study in COPD

NCT00122434
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 83 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 26, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 26, 2026, 11:13 PM EDT